Avalon GloboCare Beheer

Beheer criteriumcontroles 4/4

De CEO Avalon GloboCare is David Jin, benoemd in Sep2016, heeft een ambtstermijn van 8.17 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 330.00K, bestaande uit 100% salaris en 0% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 9.67% van de aandelen van het bedrijf, ter waarde $ 321.36K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 8.1 jaar en 6.3 jaar.

Belangrijke informatie

David Jin

Algemeen directeur

US$330.0k

Totale compensatie

Percentage CEO-salaris	100.0%
Dienstverband CEO	8.2yrs
Eigendom CEO	9.7%
Management gemiddelde ambtstermijn	8.1yrs
Gemiddelde ambtstermijn bestuur	6.3yrs

Recente managementupdates

We Think Some Shareholders May Hesitate To Increase Avalon GloboCare Corp.'s (NASDAQ:ALBT) CEO Compensation

Oct 06

Recent updates

We Think Some Shareholders May Hesitate To Increase Avalon GloboCare Corp.'s (NASDAQ:ALBT) CEO Compensation

Oct 06

Have Insiders Been Buying Avalon GloboCare Corp. (NASDAQ:AVCO) Shares This Year?

Jan 30

Is Avalon GloboCare (NASDAQ:AVCO) Using Too Much Debt?

Jan 04

What Percentage Of Avalon GloboCare Corp. (NASDAQ:AVCO) Shares Do Insiders Own?

Nov 30

Analyse CEO-vergoeding

Hoe is David Jin's beloning veranderd ten opzichte van Avalon GloboCare's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$15m
Jun 30 2024	n/a	n/a	-US$15m
Mar 31 2024	n/a	n/a	-US$15m
Dec 31 2023	US$330k	US$330k	-US$17m
Sep 30 2023	n/a	n/a	-US$10m
Jun 30 2023	n/a	n/a	-US$13m
Mar 31 2023	n/a	n/a	-US$13m
Dec 31 2022	US$360k	US$360k	-US$12m
Sep 30 2022	n/a	n/a	-US$12m
Jun 30 2022	n/a	n/a	-US$8m
Mar 31 2022	n/a	n/a	-US$9m
Dec 31 2021	US$360k	US$360k	-US$9m
Sep 30 2021	n/a	n/a	-US$10m
Jun 30 2021	n/a	n/a	-US$11m
Mar 31 2021	n/a	n/a	-US$12m
Dec 31 2020	US$1m	US$360k	-US$13m
Sep 30 2020	n/a	n/a	-US$15m
Jun 30 2020	n/a	n/a	-US$16m
Mar 31 2020	n/a	n/a	-US$17m
Dec 31 2019	US$935k	US$540k	-US$18m
Sep 30 2019	n/a	n/a	-US$15m
Jun 30 2019	n/a	n/a	-US$14m
Mar 31 2019	n/a	n/a	-US$11m
Dec 31 2018	US$400k	US$400k	-US$8m
Sep 30 2018	n/a	n/a	-US$7m
Jun 30 2018	n/a	n/a	-US$5m
Mar 31 2018	n/a	n/a	-US$4m
Dec 31 2017	US$200k	US$200k	-US$3m

Compensatie versus markt: De totale vergoeding ($USD 330.00K ) David } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 650.91K ).

Compensatie versus inkomsten: De vergoeding van David is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

David Jin (56 yo)

8.2yrs

Tenure

US$330,000

Compensatie

Dr. David K. Jin, M.D., Ph D., serves as the Chief Executive Officer and President of Avalon Globocare Corp since September 14, 2016. Dr. Jin is a Senior Translational Scientist at the Howard Hughes Medica...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
David Jin	CEO, President & Director	8.2yrs	US$330.00k	9.67% $ 321.4k
Luisa Ingargiola	Chief Financial Officer	7.8yrs	US$350.00k	0% $ 0
Meng Li	COO & Secretary	8.1yrs	US$280.24k	3.22% $ 107.1k

8.1yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ALBT is doorgewinterd en ervaren (gemiddelde ambtstermijn van 8.1 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
David Jin	CEO, President & Director	8.2yrs	US$330.00k	9.67% $ 321.4k
Robert Langer	Member of Scientific & Clinical Advisory Board	5.6yrs	geen gegevens	geen gegevens
William Stilley	Independent Director	6.3yrs	US$103.67k	0% $ 0
Steven Sanders	Independent Director	6.3yrs	US$103.67k	0% $ 0
Shahin Rafii	Member of Scientific & Clinical Advisory Board	no data	geen gegevens	geen gegevens
Wilbert Tauzin	Director	7yrs	US$38.05k	0% $ 0
Tevi Troy	Independent Director	6.4yrs	US$93.67k	0% $ 0
Lourdes Felix	Independent Director	1.8yrs	US$91.76k	0% $ 0
Wenzhao Lu	Chairman of the Board	8.1yrs	US$100.00k	22.42% $ 745.4k
James Gajewski	Head of Scientific & Clinical Advisory Board	6.3yrs	geen gegevens	geen gegevens
Yen-Michael Hsu	Member of Scientific & Clinical Advisory Board	no data	geen gegevens	geen gegevens
Wenchun Qu	Member of Scientific & Clinical Advisory Board	no data	geen gegevens	geen gegevens

6.3yrs

Gemiddelde duur

60.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ALBT wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.3 jaar).

Avalon GloboCare Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Avalon GloboCare Appoints Dr. Charles Cavo to its Scientific and Clinical Advisory Board

Avalon GloboCare Corp., Annual General Meeting, Oct 08, 2024

We Think Some Shareholders May Hesitate To Increase Avalon GloboCare Corp.'s (NASDAQ:ALBT) CEO Compensation

Avalon GloboCare Corp., Annual General Meeting, Oct 12, 2023

Avalon Globocare Appoints Lourdes Felix, to Its Board of Directors

Avalon GloboCare Corp., Annual General Meeting, Dec 29, 2022

Recent updates

Third quarter 2024 earnings released: US$1.82 loss per share (vs US$2.06 loss in 3Q 2023)

Avalon GloboCare Appoints Dr. Charles Cavo to its Scientific and Clinical Advisory Board

Avalon GloboCare Announces 1-for-15 Reverse Stock Split as Part of Nasdaq Compliance Plan

Avalon GloboCare Corp., Annual General Meeting, Oct 08, 2024

Avalon GloboCare Corp. announced delayed 10-Q filing

Avalon GloboCare Corp. Provides Update on the Launch of the KetoAir Breathalyzer at Hack Your Health by KetoCon 2024 Conference

Avalon GloboCare Receives Notice from Nasdaq Regarding Delayed Quarterly Report on Form 10-Q for the Fiscal Quarter Ended March 31, 2024

Avalon GloboCare Corp. announced delayed 10-Q filing

The Nasdaq Stock Market, LLC Grants Avalon GloboCare a 180-Day Extension to October 28, 2024 to Regain Compliance with the Minimum Bid Price Requirement

Avalon GloboCare Corp. Announces Launch of U.S. Sales of KetoAir Breathalyzer at the Hack Your Health by KetoCon 2024 Conference

Avalon GloboCare Corp. announced delayed annual 10-K filing

Third quarter 2023 earnings released: US$0.14 loss per share (vs US$0.56 loss in 3Q 2022)

Avalon Globocare Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market as Set Forth in Nasdaq Listing Rule 5550(a)(2)

New major risk - Share price stability

We Think Some Shareholders May Hesitate To Increase Avalon GloboCare Corp.'s (NASDAQ:ALBT) CEO Compensation

Avalon GloboCare Corp., Annual General Meeting, Oct 12, 2023

Second quarter 2023 earnings released: US$0.25 loss per share (vs US$0.23 loss in 2Q 2022)

Avalon GloboCare Corp. announced delayed 10-Q filing

Full year 2022 earnings released: US$1.28 loss per share (vs US$1.07 loss in FY 2021)

Avalon GloboCare Corp. announced that it expects to receive $11 million in funding

Avalon GloboCare Regains Compliance with the Minimum Bid Requirement

Avalon Globocare Appoints Lourdes Felix, to Its Board of Directors

Avalon GloboCare Corp., Annual General Meeting, Dec 29, 2022

Third quarter 2022 earnings released: US$0.056 loss per share (vs US$0.024 loss in 3Q 2021)

Insufficient new directors

Avalon GloboCare Corp. (NasdaqCM:AVCO) entered into an agreement to acquire 60% stake in Laboratory Services MSO, LLC for $31 million.

We Think Avalon GloboCare (NASDAQ:AVCO) Has A Fair Chunk Of Debt

Avalon GloboCare Receives Second Letter from the Staff of Nasdaq

Second quarter 2022 earnings released: US$0.023 loss per share (vs US$0.028 loss in 2Q 2021)

Avalon GloboCare Corp. Announces New Study Featuring AI-Enhanced Protein Design Technology Targeting Glucose Transporter Against Cancer

Avalon GloboCare Corp. announced that it has received $3.718943 million in funding

Insufficient new directors

Would Avalon GloboCare (NASDAQ:AVCO) Be Better Off With Less Debt?

Avalon GloboCare Corp. Appoints Hongxing Liu to Scientific and Clinical Advisory Board

First quarter 2022 earnings released: US$0.023 loss per share (vs US$0.028 loss in 1Q 2021)

Insufficient new directors

Full year 2021 earnings released: US$0.11 loss per share (vs US$0.16 loss in FY 2020)

Does Avalon GloboCare (NASDAQ:AVCO) Have A Healthy Balance Sheet?

Avalon GloboCare Expands its Cellular Immuno-Oncology Platform with the Addition of Novel Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapies

Third quarter 2021 earnings released: US$0.024 loss per share (vs US$0.04 loss in 3Q 2020)

Here's Why Avalon GloboCare (NASDAQ:AVCO) Can Afford Some Debt

Director William Stilley has joined 3rd company board

Second quarter 2021 earnings released: US$0.028 loss per share (vs US$0.039 loss in 2Q 2020)

Avalon GloboCare Corp.(NasdaqCM:AVCO) dropped from Russell Microcap Value Index

Avalon GloboCare Corp. (NasdaqCM:AVCO) entered into a definitive agreement to acquire Hebei Senlang Biotechnology Inc., Ltd. for approximately CNY 640 million.

Avalon Globocare to acquire SenlangBio in all-stock deal

First quarter 2021 earnings released: US$0.028 loss per share (vs US$0.043 loss in 1Q 2020)

Is Avalon GloboCare (NASDAQ:AVCO) A Risky Investment?

Full year 2020 earnings released: US$0.16 loss per share (vs US$0.24 loss in FY 2019)

A Look At Avalon GloboCare's (NASDAQ:AVCO) Share Price Returns

New 90-day high: US$1.59

Have Insiders Been Buying Avalon GloboCare Corp. (NASDAQ:AVCO) Shares This Year?

New 90-day high: US$1.33

Is Avalon GloboCare (NASDAQ:AVCO) Using Too Much Debt?

What Percentage Of Avalon GloboCare Corp. (NASDAQ:AVCO) Shares Do Insiders Own?

Third quarter 2020 earnings released: US$0.04 loss per share

New 90-day low: US$1.12

Avalon GloboCare Provides Clinical Updates on its CAR-T Immuno-Oncology and Allogeneic Mesenchymal Stromal Cell (MSC) Therapy Programs Following Successful Completion of Phase I AVA-001 Clinical Trial

New 90-day low: US$1.15

New 90-day low - US$1.54

First half earnings released

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden